fbpx

Tau Capital edging closer to sale of last holding

Tau Capital has completed the sale of its investment in Lucent for $250,000 and is working on the sale of Stopharm. They have a $7m offer for their investment but Stopharm needs a cash injection so they are exploring whether they can lend Stopharm $700,00 out of the proceeds of the sale and then sell the loan on at a discount (so the proceeds of the Stopharm exit maybe between $6.3m and $7m).

Once the deal gets done (and of course there is no guarantee that it will), the Board is wondering whether they can sell the company on as a cash shell – watch this space.

Tau Capital edging closer to sale of last holding

Leave a Reply

Your email address will not be published. Required fields are marked *

NULL